Canada Markets open in 1 hr 46 mins

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0900-0.0300 (-1.42%)
At close: 4:00PM EDT
2.0900 0.00 (0.00%)
Pre-Market: 06:28AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.1200
Open2.1200
Bid2.0800 x 1000
Ask2.1000 x 4000
Day's Range2.0600 - 2.1400
52 Week Range2.0000 - 9.0800
Volume839,348
Avg. Volume915,921
Market Cap258.677M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-1.3200
Earnings DateAug. 04, 2021 - Aug. 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.89
  • GlobeNewswire

    Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress

    Nine accepted abstracts demonstrate broad potential of the company’s HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disordersBOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22. Clinical and pre-clinical data from across the com

  • GlobeNewswire

    Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

    Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present Opportunities for Future Partnerships BOSTON and LONDON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today will present on the company’s discovery and research efforts in hematopoietic stem cell (HSC) gene therapy, including an update on the OTL-104

  • GlobeNewswire

    Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

    Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today an